NextFin news, The U.S. Food and Drug Administration (FDA) approved on Monday a new eye drop medication called Vizz, developed by Lenz Therapeutics, designed to improve near vision in adults suffering from presbyopia, a common age-related condition that impairs the ability to focus on close objects.
Presbyopia typically affects people starting in their early 40s as the eye's lens loses elasticity, making near tasks such as reading or using smartphones difficult. Until now, options included reading glasses, contact lenses, or surgical interventions.
Vizz contains aceclidine, which contracts the pupil to less than two millimeters, creating a 'pinhole effect' that increases the eye's depth of focus without distorting distance vision. This effect allows users to see near objects more clearly for up to 10 hours after a single daily application.
The FDA approval was based on data from three Phase 3 clinical trials involving over 600 participants. These studies demonstrated that more than 70% of users gained at least three lines of improvement on a standard near-vision eye chart within 30 minutes of application, with effects lasting throughout most of the day.
Common side effects reported included mild eye irritation, temporary dim vision especially in low light, and headaches. The FDA recommends baseline retinal exams before prescribing the drops due to rare risks associated with pupil constriction, such as retinal detachment.
Marc Bloomenstein, a clinical investigator at Schwartz Laser Eye Care Center in Arizona, stated, "I believe this will be a very useful solution for both optometrists and ophthalmologists, who can now offer patients a highly effective and much-needed treatment for presbyopia—one that could immediately become the standard of care."
Lenz Therapeutics plans to begin distributing Vizz samples to eye-care providers in October 2025, with a full commercial rollout expected by the end of the year. The drops will be available by prescription only.
This new treatment offers a practical, non-invasive alternative for millions of adults frustrated with the inconvenience of reading glasses or the risks of surgery, marking a significant advancement in vision care.
Explore more exclusive insights at nextfin.ai.
